Enfermedad metabólica ósea postrasplante

  1. Federico Hawkins Carranza 1
  2. María Begoña López Álvarez
  3. María Ángeles Valero Samuy
  4. Sonsoles Guadalix Iglesias
  5. María Soledad Librizzi
  6. Guillermo Martínez Díaz Guerra
  1. 1 Real Academia de Medicina; Instituto de Investigación i+12, Hospital Univ. 12 de Octubre; Facultad de Medicina UCM
Revista:
Anales de la Real Academia Nacional de Medicina

ISSN: 0034-0634

Año de publicación: 2019

Número: 136

Páginas: 249-255

Tipo: Artículo

DOI: 10.32440/AR.2019.136.03.REV03 DIALNET GOOGLE SCHOLAR lock_openAcceso abierto editor

Otras publicaciones en: Anales de la Real Academia Nacional de Medicina

Resumen

La osteoporosis puede ser una complicación importante del trasplante de órganos (TxO), que puede llevar a menor calidad de vida y mayor riesgo de fracturas. El objetivo ha sido revisar el estado actual de este riesgo, en base a nuestra experiencia en relación, a la fi- siopatología y tratamiento. Después del TxO, los esteroides son el agente más nocivo sobre el remodelado óseo, con pérdida ósea importante en los primeros meses y una tendencia posterior a la recupera- ción en algunos, pero a persistir en otros. Junto a los esteroides, la ciclosporina y otros inmunosupresores, pueden contribuir al deterioro del remodelado óseo. El tratamiento actual, es objeto de estudios y ensayos clínicos, siendo los bisfosfonatos los agentes más utilizados. De entre ellos hay más experiencia con el alendronato, rise- dronato y últimamente con el ácido zolendronico. Su eficacia es similar, y los efectos se- cundarios deben vigilarse durante su administración. Finalmente, la administración de calcio y vitamina D es recomendable, dado el frecuente déficit de esta vitamina en estos pacientes acentuada por los esteroides.

Referencias bibliográficas

  • Lofdahl E, Radegran G. Osteoporosisfollowing heart transplantation and immunosuppressive therapy. Transplant Rev 107; 201: 232-239.
  • Stein E, Ebeling P, Shane E. Post-transplantation osteoporosis. Endocrinol Metab Clin North Am 2007; 36(4): 937-963.
  • Kulak CA, Borba VZ, Kulak Júnior J, Campos DJ, Shane E. Posttransplantation osteoporosis. Arq Bras Endocrinol Metabol 2010; 54(2): 143-149.
  • Monegal A, Navasa M, Guanabens N, et al. Bone disease after liver transplantation: a long-term prospective study of bone mass changes, hormonal status and histomorphometric characteristics. Osteoporos Int 2001; 12(6): 484-492.
  • Guichelaar MM, Kendall R, Malinchoc M, Hay JE. Bone mineral density before and after OLT: long-term follow-up and predictive factors. Liver Transpl 2006; 12(9): 1390-1402.
  • Hamburg SM, Piers DA, van den Berg AP, Slooff MJ, Haagsma EB. Bone mineral density in the long term after liver transplantation. Osteoporos Int 2000; 11(7): 600-606.
  • Vedi S, Greer S, Skingle SJ, et al. Mechanism of bone loss after liver transplantation: a histomorphometric analysis. J Bone Miner Res 1999; 14(2):281-287.
  • Ninkovic M, Love SA, Tom B, Alexander GJ, Compston JE. High prevalence of osteoporosis in patients with chronic liver disease prior to liver transplantation. Calcif Tissue Int 2001; 69(6): 321-326.
  • Guichelaar MM, Kendall R, Malinchoc M, Hay JE. Bone mineral density before and after OLT: longterm follow-up and predictive factors. Liver Transpl 2006; 12(9):1390-1402.
  • Floreani A, Mega A, Tizian L et al. Bone metabolism and gonad function in male patients undergoing liver transplantation: a two-year longitudinal study. Osteoporos Int 2001; 12(9): 749-754.
  • García-Delgado I, Prieto S, Gil-Fraquas L, Robles E, Rufilanchas JJ, Hawkins F. Calcitonin, etidronate, and calcidiol treatment in bone loss after cardiac transplantation. Calcif Tissue Int 1997; 60(2): 155-159.
  • Valero MA, Loinaz C, Larrodera L, León M, Moreno E, Hawkins F. Calcitonin and bisphosphonates treatment in bone loss after liver transplantation. Calcif Tissue Int 1995; 57(1): 15-19.
  • Hawkins FG, León M, López MB, et al. Bone loss and turnover in patients with liver transplantation. Hepatogastroenterology 1994; 41(2): 158-161.
  • López MB, González Pinto I, Hawkins F, et al. Effect of liver transplantation and immunosuppressive treatment on bone mineral density. Transplant Proc 1992; 24(6): 3044-3046.
  • Rodino MA, Shane E. Osteoporosis after organ transplantation. Am J Med 1998; 104(5): 459-469.
  • Wang H, Jiang W, Zhou Z, et al. Liver transplantation in mainland China: the overview of CLTR 2011 annual scientific report. Hepatobiliary Surg Nutr 2013; 2(4):188-197.
  • Dolgos S, Hartmann A, Isaksen GA, et al. Osteoporosis is a prevalent finding in patients with solid organ failure awaiting transplantation - a population based study. Clin Transplant 2010; 24(5): E145-152.
  • Danovitch GM, Cohen DJ, Weir MR, et al. Current status of kidney and pancreas transplantation in the United States, 1994-2003. Am J Transplant 2005; 5(4 Pt 2): 904-915.
  • Bianda T, Linka A, Junga G, et al. Prevention of osteoporosis in heart transplant recipients: a comparison of calcitriol with calcitonin and pamidronate. Calcif Tissue Int 2000; 67(2): 116-121.
  • Negri AL, Perrone S, Gallo R, Bogado CE, Zanchetta JR. Osteoporosis following heart transplantation. Transplant Proc 1996; 28(6): 3321-3324.
  • Thiébaud D, Krieg MA, Gillard-Berguer D, Jacquet AF, Goy JJ, Burckhardt P. Cyclosporine induces high bone turnover and may contribute to bone loss after heart transplantation. Eur J Clin Invest 1996; 26(7): 549-555.
  • Eshane E, Epstein S. Transplantation osteoporosis. Transplant Rev 2001: 15: 11-13.
  • Shane E, Rivas M, McMahon DJ, Staron RB, Silverberg SJ, Seibel MJ. Bone loss and turnover after cardiac transplantation. J Clin Endocrinol Metab 1997; 82(5): 1497-1506.
  • Pisani B, Mullen GM. Prevention of osteoporosis in cardiac transplant recipients. Curr Opin Cardiol 2002; 17(2): 160-164.
  • Maalouf NM, Shane E. Osteoporosis after solid organ transplantation. J Clin Endocrinol Metab 2005; 90(4): 2456-2465.
  • Chauhan V, Ranganna KM, Chauhan N, Vaid M, Kelepouris E. Bone disease in organ transplant patients: pathogenesis and management. Postgrad Med 2012; 124(3): 80-90.
  • Kulak CA, Borba VZ, Kulak Júnior J, Shane E. Transplantation osteoporosis. Arq Bras Endocrinol Metabol 2006; 50(4): 783-792.
  • Stein E, Ebeling P, Shane E. Post-transplantation osteoporosis. Endocrinol Metab Clin NorthAcad Sci U S A 2005; 102(47): 17130-17135.
  • Sun L, Blair HC, Peng Y, et al. Calcineurin regulates bone formation by the osteoblast Proc Natl Acad Sci U S A 2005; 102(47): 17130-17135
  • Sun L, Peng Y, Zaidi N, et al. Evidence that calcineurin is required for the genesis of bone-resorbing osteoclasts.Am J Physiol Renal Physiol 2007; 292(1): F285-291.
  • Cvetkovic M, Mann GN, Romero DF, et al. The deleterious effects of long-term cyclosporine A, cyclosporine G, and FK506 on bone mineral metabolism in vivo. Transplantation 1994 27; 57(8): 1231-1237.
  • Epstein S. Post-transplantation bone disease: the role of immunosuppressive agents and the skeleton. J Bone Miner Res 1996; 11(1): 1-7.
  • Bowman AR, Sass DA, et al. The role of testosterone in cyclosporine-induced osteopenia. J Bone Miner Res 1997; 12(4): 607-615.
  • Martínez Díaz-Guerra G, Gómez R, Jódar E, Loinaz C, Moreno E, Hawkins F. Long-term follow-up of bone mass after orthotopic liver transplantation: Effect of steroid withdrawal from the immunosuppressive regimen. Osteoporos Int 2002; 13(2): 147-150.
  • Aroldi A, Tarantino A, Montagnino G, Cesana B, Cocucci C, Ponticelli C. Effects of three immunosuppressive regimens on vertebral bone density in renal transplant recipients: a prospective study. Transplantation 1997 15; 63(3): 380-386.
  • Shane E, Rivas MC, Silverberg SJ, Kim TS, Staron RB, Bilezikian JP. Osteoporosis after cardiac transplantation. Am J Med 1993; 94(3): 257-264.
  • Anijar JR, Szejnfeld VL, Almeida DR, Fernandes AR, Ferraz MB. Reduced bone mineral density in men after heart transplantation. Braz J Med Biol Res 1999; 32(4): 413-420.
  • Stempfle HU, Werner C, Siebert U, et al. The role of tacrolimus (FK506)-based immunosuppression on bone mineral density and bone turnover after cardiac transplantation: a prospective, longitudinal, randomized, double-blind trial with calcitriol. Transplantation 2002 27; 73(4): 547- 552.
  • Goffin E, Devogelaer JP, Lalaoui A, et al. Tacrolimus and low-dose steroid immunosuppression preserves bone mass after renal transplantation. Transpl Int 2002; 15(2-3): 73-80.
  • Bryer HP, Isserow JA, Armstrong EC, et al. Azathioprine alone is bone sparing and does not alter cyclosporin A-induced osteopenia in the rat. J Bone Miner Res 1995; 10(1): 132-138.
  • Hayashi K, Yamaguchi T, Yano S, et al. BMP/Wnt antagonists are upregulated by dexamethasone in osteoblasts and reversed by alendronate and PTH: potential therapeutic targets for glucocorticoidinduced osteoporosis. Biochem Biophys Res Commun 2009 6; 379(2): 261-266.
  • Giannini S, Nobile M, Ciuffreda M, et al. Longterm persistence of low bone density in orthotopic liver transplantation. Osteoporos Int 2000; 11(5): 417-424.
  • Goffin E, Devogelaer JP, Depresseux G, Squifflet JP, Pirson Y. Osteoporosis after organ transplantation. Lancet 2001 19; 357(9268): 1623.
  • Guichelaar MM, Malinchoc M, Sibonga J, Clarke BL, Hay JE. Immunosuppressive and postoperative effects of orthotopic liver transplantation on bone metabolism. Liver Transpl 2004; 10(5): 638-647.
  • Gilfraguas L, Guadalix S, Martínez G, et al. Bone loss after heart transplant: effect of alendronate, etidronate, calcitonin and calcium plusvitamin D3. Prog Transplant 2012; 22(3): 237-243.
  • Nel JD, Epstein S. Metabolica bone disease in the post-transplant population. Med Clin Nam 2016; 100: 569-586.
  • Guadalix S, Martínez-Díaz Guerra G, Lora D, et al. Effect of early risedronate treatment onbone mineral density and bone turnover markers after liver transplantation: a prospective single-center study. Transplant Int 2011; 24 (7): 657-665.
  • Librizzi MS, Guadalix S, Martínez-Díaz Guerra G, et al. Trabecular bone score in patients with liver transplants after1 year of risedronate treatment. Transpl Int 2016; 29(3): 331-337. Am 2007; 36(4): 937-963. 29. Sun L, Blair HC, Peng Y, et al. Calcineurin regulates bone formation by the osteoblast Proc Natl
Fuente de los datos: Dialnet